Oncology On targeted radiotherapeutics, with Marc Hedrick Dr Marc Hedrick, president and CEO of Plus Therapeutics, discusses developing targeted radiotherapeutics.
News AZ/BenevolentAI collab achieves AI-enabled further milestone... Two additional novel AI-generated targets for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) have been discovered using the Benevolent Platform and selected for AstraZ
News NHS risks missing out on independent prescriber benefits Gaps in support could undermine a wave of new independent prescribers entering the NHS and a push for more community-based care, warns a new report.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
